Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Levetiracetam | |
| Synonyms |
levetiracetam LEVETIRACETAM (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide Levetiracetam 1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)- Keppra |
|
| Definitions |
A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C47581 |
|
| Accepted_Therapeutic_Use_For |
Treating partial-onset seizures in patients with epilepsy.
|
|
| ALT_DEFINITION |
A drug used to treat seizures (involuntary muscle movements) caused by epilepsy (a group of brain disorders). Keppra is being studied in the treatment of seizures in patients with cancer that has spread to the brain. It is a type of anticonvulsant.
|
|
| CAS_Registry |
102767-28-2
|
|
| CHEBI_ID |
CHEBI:6437
|
|
| Chemical_Formula |
C8H14N2O2
|
|
| code |
C47581
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712 |
|
| Contributing_Source |
FDA GDC
|
|
| DEFINITION |
A pyrrolidine with antiepileptic activity. The exact mechanism through which levetiracetam exerts its effects is unknown but does not involve inhibitory and excitatory neurotransmitter activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.
|
|
| FDA_UNII_Code |
44YRR34555
|
|
| FULL_SYN |
levetiracetam LEVETIRACETAM (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide Levetiracetam 1-Pyrrolidineacetamide, Alpha-ethyl-2-oxo-,(S)- Keppra
|
|
| Is_Value_For_GDC_Property | ||
| label |
Levetiracetam
|
|
| Legacy Concept Name |
Levetiracetam
|
|
| Maps_To |
Levetiracetam
|
|
| NCI_Drug_Dictionary_ID |
526173
|
|
| PDQ_Closed_Trial_Search_ID |
526173
|
|
| PDQ_Open_Trial_Search_ID |
526173
|
|
| Preferred_Name |
Levetiracetam
|
|
| prefixIRI |
Thesaurus:C47581
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C0377265
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |